CROSSROADS-1: Treatment Outcomes among Tezspire Users: A Claims Data Study (20230159)

Study identification

• EU PAS number:
  EUPAS1000000062
• Study ID:
  1000000062
• Official title and acronym:
  CROSSROADS-1: Treatment Outcomes among Tezspire Users: A Claims Data Study (20230159)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  This will be a descriptive, retrospective cohort study conducted utilizing the IQVIA PharMetrics® Plus database to assess the reduction of asthma exacerbations and healthcare resource utilization among Tezspire users.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Amgen

United States

IQVIA

United Kingdom

Study timelines

Date when funding contract was signed

Planned: 08/06/2022

Actual: 08/06/2022

Study start date

Planned: 24/01/2024

Actual: 24/01/2024

Data analysis start date

Planned: 31/03/2025

Actual: 18/11/2024

Date of final study report

Planned: 01/02/2026

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Amgen 100%

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

20230159